United Medical Devices

playboycondoms.com

Playboy Condoms launched in 2010 and has seen the fastest growth in the condom segment out of any other brand. Since the launch, Playboy Condoms has secured distribution in over 80 countries around the world and our products are now on the shelves of major convenience stores and pharmacies in over 30 countries, with the number of retailers increasing by the quarter, with many more almost through local health requirements to receive goods. Since the launch of Playboy Condoms, we have doubled our world wide shipments of containers year over year.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

news image

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

news image

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

news image

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More

Business Insights

TRIS PHARMA ANNOUNCES DEVELOPMENT OF A VERY LOW SODIUM AND ONCE-NIGHTLY OXYBATE FORMULATION

Tris Pharma, Inc. | July 28, 2022

news image

Tris Pharma, Inc. a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that it has successfully developed an oxybate formulation for the treatment of cataplexy or excessive daytime sleepiness n patients 7 years of age and older with narcolepsy that has the potential to be significantly advantageous to existing approved therapies, such as Jazz Pharmaceuticals' blockbuster XYWAV® and XYREM® franchise. The Tris oxybate formulation is believed to pr...

Read More
news image

Pharma Tech

PALATIN ANNOUNCES INTENT TO EFFECT REVERSE STOCK SPLIT

Palatin Technologies, Inc. | August 20, 2022

Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 and the Company's common stock is expected to begin trading on a split-adjusted basis when t...

Read More
news image

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More
news image

Business Insights

MILLIPORESIGMA INVESTS $ 286 MILLION IN U.S. DRUG SAFETY TESTING CAPACITY

MilliporeSigma | November 16, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company's site in Rockville, Maryland, USA. This will significantly increase the company's ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fund...

Read More
news image

Business Insights

TRIS PHARMA ANNOUNCES DEVELOPMENT OF A VERY LOW SODIUM AND ONCE-NIGHTLY OXYBATE FORMULATION

Tris Pharma, Inc. | July 28, 2022

Tris Pharma, Inc. a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that it has successfully developed an oxybate formulation for the treatment of cataplexy or excessive daytime sleepiness n patients 7 years of age and older with narcolepsy that has the potential to be significantly advantageous to existing approved therapies, such as Jazz Pharmaceuticals' blockbuster XYWAV® and XYREM® franchise. The Tris oxybate formulation is believed to pr...

Read More